H.R. 1117 · 118th Congress
Advancing Safe Medications for Moms and Babies Act of 2023
Key: what the circles and colors mean
Each circle is a bill. The ring fills as it moves through Congress:
Under the number: the Yea · Nay count of its final (or latest) recorded vote. On a member's page, the small badge is how that member voted: Y Yea / Aye, N Nay / No, P Present, – Not voting.
Gold and violet are only for Yea and Nay; they never mean a party. A member's party is the letter on their photo.
Never voted on. It didn't reach a floor vote before the 118th Congress ended, so it expired. A bill has to be introduced again to be considered in a new Congress.
D
CastorSponsor30 cosponsors · 28 D, 2 R
R
Fitzpatrick
LU
D
Underwood
SD
D
DelBene
AK
D
Kuster
JM
D
Morelle
WN
D
Nickel
CP
D
Pappas
RT
D
Tlaib
SW
D
Wild
LB
D
Blunt Rochester
SC
D
Casten
SD
D
Davids
RM
D
Menendez
YC
D
Caraveo
JG
D
Gottheimer
MP
D
Peltola
RK
D
Kelly
SL
D
Lynch
DG
D
Goldman
MP
D
Pocan
CA
D
Allred
KM
D
Manning
JN
D
Nadler
CP
D
Pingree
TS
D
Sewell
AC
D
Craig
SP
D
Peters
LF
D
Frankel
AA
D
Adams
DB
R
Bacon2 signed on when it was introduced; the rest joined later. Cosponsors who withdrew aren't shown.
This bill establishes programs and requirements to support the inclusion of pregnant and lactating women in clinical research.
What it does: CRS summary · Introduced in House · Feb 21, 2023
Advancing Safe Medications for Moms and Babies Act of 2023
This bill establishes programs and requirements to support the inclusion of pregnant and lactating women in clinical research.
For example, the bill requires the Department of Health and Human Services to align the Food and Drug Administration's regulations for human subjects in clinical trials with other departmental regulations for pregnant women in clinical research.
The bill also establishes (1) a national online clearinghouse with information about clinical trials that enroll pregnant and lactating women, (2) an advisory committee to help coordinate federal activities with respect to clinical research for pregnant and lactating women, and (3) an educational campaign on the importance of including pregnant and lactating women in clinical research.
The National Institutes of Health must also prioritize certain research projects on new and existing medications for pregnant and lactating women based on need, feasibility, and the potential impact of the research.
Written by the nonpartisan Congressional Research Service. All summary versions on Congress.gov
About this bill and sources
Official title: Advancing Safe Medications for Moms and Babies Act of 2023
Latest action (Mar 3, 2023): Referred to the Subcommittee on Health.
Policy area: Health · Origin: House · Introduced: Feb 21, 2023
Official page on Congress.gov · Bill text (GovInfo) · Status record (XML)
No recorded floor vote found.